Volume 14, Number 8—August 2008
Research
Genetic and Serologic Properties of Zika Virus Associated with an Epidemic, Yap State, Micronesia, 2007
Robert S. Lanciotti*
, Olga L. Kosoy*, Janeen J. Laven*, Jason O. Velez*, Amy J. Lambert*, Alison J. Johnson*, Stephanie M. Stanfield*, and Mark R. Duffy*
, Olga L. Kosoy*, Janeen J. Laven*, Jason O. Velez*, Amy J. Lambert*, Alison J. Johnson*, Stephanie M. Stanfield*, and Mark R. Duffy*Table 2
Neutralization testing with heterologous flaviviruses of patients infected with ZIKV, Yap State, Micronesia, 2007*
| Patient | Days after onset | PRNT90 titer | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ZIKV | DENV1 | DENV2 | DENV3 | DENV4 | JEV | YFV | WNV | SLEV | MVEV | ||
| Primary flavivirus ZIKV | |||||||||||
| 822a | 5 | 320 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 |
| 822b | 10 | 2,560 | 10 | 10 | 10 | 10 | <10 | <10 | <10 | <10 | <10 |
| 822c | 24 | 5,120 | 10 | 10 | 10 | 10 | <10 | <10 | <10 | <10 | <10 |
| 830a | 2 | <10 | <10 | NT‡ | NT | NT | NT | NT | NT | NT | NT |
| 830b | 21 | 2,560 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 |
| 849a | 3 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 |
| 849b | 18 | 10,240 | <10 | <10 | <10 | <10 | <10 | 20 | <10 | <10 | <10 |
| 862a | 6 | 320 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 |
| 862b | 20 | 2,560 | 10 | 10 | <10 | <10 | <10 | <10 | <10 | 10 | <10 |
| Secondary flavivirus ZIKV (probable) | |||||||||||
| 817a | 1 | 80 | 80 | 160 | 320 | 160 | <10 | <10 | <10 | 40 | 40 |
| 817b | 19 | 10,240 | 2,560 | 20,480 | 5,120 | 5,120 | 20 | 320 | 160 | 1,280 | 640 |
| 833a | 1 | 160 | 320 | 80 | 40 | 20 | <10 | <10 | <10 | <10 | <10 |
| 833b | 19 | 81,920 | 20,480 | 5,120 | 5,120 | 1,280 | <10 | <10 | 80 | 320 | 320 |
| 844a | 2 | 20 | 1,280 | 640 | 320 | 160 | <10 | <10 | 5 | 20 | 20 |
| 844b | 16 | 10,240 | 40,980 | 10,240 | 5,120 | 1,280 | 5 | <10 | 160 | 640 | 640 |
| 955a | 1 | 40 | 1,280 | 640 | 160 | 320 | <10 | <10 | <10 | 20 | 20 |
| 955b | 14 | 163,840 | 81,920 | 20,480 | 10,240 | 5,120 | 10 | <10 | 640 | 2,560 | 1,280 |
| 968a | 1 | 80 | 320 | 320 | 80 | 40 | <10 | <10 | <10 | 40 | 20 |
| 968b | 3 | 10,240 | 640 | 640 | 160 | 160 | <10 | <10 | 10 | 40 | 20 |
| 839a | 3 | <10 | <10 | 10 | <10 | <10 | <10 | 40 | <10 | <10 | <10 |
| 839b | 20 | 10,240 | 40 | 320 | 80 | 80 | <10 | 640 | 40 | 80 | 80 |
| 847a | 5 | <10 | <10 | <10 | <10 | <10 | <10 | 640 | <10 | <10 | <10 |
| 847b | 8 | 2,560 | 40 | 320 | 160 | 40 | <10 | 1,280 | 80 | 320 | 320 |
*PRNT90 titer, 90% plaque-reduction neutralization test titer; ZIKV, Zika virus; DENV, dengue virus; JEV, Japanese encephalitis virus; YFV, yellow fever virus; WNV, West Nile virus; SLEV, St. Louis encephalitis virus; MVEV, Murray Valley encephalitis virus; NT, not tested (sample depleted).
